Designing a strategy to promote safe, innovative off-label use of medications

American Journal of Medical Quality

Volumn 21, Issue 4, 2006, Pages 255-261

  Ansani, Nicole ^a   Sirio, Carl ^b   Smitherman, Thomas ^b   Fedutes Henderson, Bethany ^c   Skledar, Susan ^d   Weber, Robert J ^d   Zgheib, Nathalie ^b   Branch, Robert ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Rite Aid   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Formulary; Off label; Patient safety; Pharmacy Therapeutics Committee

Indexed keywords

DRUG;

ARTICLE; DRUG LABELING; HEALTH SERVICES RESEARCH; HUMAN; MEDICATION ERROR; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; QUALITY CONTROL; SAFETY; STANDARD; UNITED STATES;

DRUG LABELING; HUMANS; MEDICATION ERRORS; ORGANIZATIONAL CASE STUDIES; PENNSYLVANIA; PHARMACEUTICAL PREPARATIONS; PROGRAM DEVELOPMENT; QUALITY CONTROL; SAFETY MANAGEMENT;

EID: 33745824617     PISSN: 10628606     EISSN: 1555824X     Source Type: Journal    
DOI: 10.1177/1062860606289020     Document Type: Article

References (14)

1. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665-670.
2. Henry V. Off-label prescribing: legal implications. J Leg Med. 1999;20:365-383.
3. Ansani NT, Sirio C, Fedutes-Henderson B, et al. United States medical practice summary: innovative off-label medication use. Am J Med Qual. In press.
4. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2004. Am J Health Syst Pharm. 2005;62:378-390.
5. Mannebach MR, Ascione FJ, Gaither CA, Bagozzi RP, Cohen IRA, Ryan ML. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Am J Health Syst Pharm. 1999;56:622-628.
6. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: US Department of Health, Education, and Welfare; 1979:appendix 6, 7-14.
7. Ansani NT, Fedutes BF, Skledar SJ, et al. Practical approach to grading evidence for formulary recommendations. Am J Health Syst Pharm. 2005;62:1498-1501.
8. Agency for Healthcare Research and Quality. US Department of Health and Human Services. Available at: http://www.ahrq.gov. Accessed April 21, 2005.
9. Johnson LJ. Off-label prescribing and the standard of care. Med Econ. 2001;78:97.
10. Longe RL, Cross GW, Riley MW. Analysis of drug reports for the P&T Committee. Hosp Formul. 1978;March:228-229.
11. Jenkings KM, Barber N. What constitutes evidence in hospital new drug decision making? Soc Sci Med. 2004;58:1757-1766.
12. Zindrick MR, Bunch WH. Orthopaedic surgery and Food and Drug Administration off-label uses. Clin Orthop. 2000;378:31-38.
13. American Academy of Pediatrics. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration. Pediatrics. 1996;98:143-145.
14. Cohen PJ. "Off-label" use of prescription drugs: legal, clinical and policy considerations. Eur J Anaesthesiol. 1997;14:231-235.